Genomic stability:
Karyotyping assays

Robust, fast and cost-effective genomic stability testing for the success of your research work

Stem cell research scientists need reassurance concerning the genomic stability of the cells they are using in their experiments. The validity of their research work relies in part on the implementation of a robust genomic quality control system.

Traditional karyotyping methods alone will not always provide the level of sensitivity required to reliably detect the most common abnormalities found in stem cells.

In addition, they are generally not suited to regular testing at each step that cells are put under stress due to their processing lead times.

With these constraints in mind, Stem Genomics has developed a range of tests to match your specific requirements and put your mind at rest.

The iCS-digital™ range: a sensitive detection solution, specifically designed for your cell type

The iCS-digital™ range has been designed to target specific abnormalities relevant to hPSCs & hMSCs, as well as aneuploidy detection. These assays use highly sensitive digital PCR (dPCR) technology, ideal for small size CNV detection that other traditional methods like G-Banding will miss.

The 5 main advantages of the iCS-digital™ PSC range:

  1. Speed: you can get your results within 3 days or even faster if you use our in-house kit.
  2. Robustness: you get a high level of confidence in your results thanks to the high sensitivity of dPCR combined with our specific set of probes.
  3. Cost effectiveness: Cheaper than G-Banding, the iCS-digital™ range enables you to test more regularly during culture, or introduce an entry level genomic screening in your process.
  4. Convenience: you can choose to do it yourself or have us perform the service for you. Regarding the service, you have several easy options to choose from to send your samples: genomic DNA, cell pellets or cells in fresh culture media (or in cell culture supernatant).
  5. Straightforward results: you get easy data analysis and interpretation of results delivered to your inbox when you choose the service, or you can download the results from the iCS- digital™ software with your kit.

Detect over 92% of recurrent abnormalities in hPSCs in record-breaking time !

Detect over 80% of recurrent abnormalities in hMSCs in record-breaking time !

Detect aneuploidy in any
human cell type in
record-breaking time !

For hPSCs only

The Duo iCS-Karyo assay* will provide you with a combined G-Banding and iCS-digital PSC solution for assessing the genomic integrity of your cells with high precision.

4 main advantages:

  1. High-resolution detection: identify the most recurrent altered regions in hPSCs, including the sub-karyotypic 20q.11.21 abnormality.
  2. Exhaustivity: G-Banding will provide you with an exhaustive structural and numerical variant analysis.
  3. Peace of mind: we provide full processing services from simultaneous metaphase chromosome preparation and DNA extraction to the final report.
  4. Straightforward results: you will get both assay results sent to you at the same time with a fully interpreted report.

* Only available in Europe, coming soon to the USA. Outside Europe, you can combine your traditional G-Banding analysis with our iCS- digital™ PSC solution.

The ultimate combined solution for hPSC in-process genomic stability testing

See what our customers say

University of Freiburg Department of Cardiology and Angiology, AG Hilgendorf
| Dr. Tsai-sang Dederichs, scientist
With Duo iCS-Karyo, Stem Genomics provides a very convenient and good quality service that makes genomic quality control easy. Communication is smooth and instructions are clear.
,,
Cellected
| Claire Richards, CEO and Founder
I would recommend the iCS-digital™ PSC to anyone who wants a good way of keeping an eye on their cells almost in real time and as a complement to traditional techniques that take a lot longer.
,,
DiNAQOR
| Kurt Jacobs, Research scientist
The iCS-digital™ PSC 24-probe kit covers a wide range of mutations in a simple test. It helps us strengthen our quality control at various stages of our workflow. For instance, it picked up the 20q amplicon that was present in some of our hiPSC lines.
,,
denovoMATRIX
| Sandra Segeletz, Head of Innovation
I would recommend the iCS-digital™ tests for anyone looking for a good genomic appraisal at minimum effort. In addition, this is an easy entry to quality control for anyone with a limited budget.
,,
GoLiver Therapeutics
| Angélique Fourrier, R&D project manager
Since we started using the iCS-digital™ PSC for routine control, we have gained a massive degree of confidence in the quality of our cells in long-term culture […] Not surprisingly, by removing the genetic instability factor from the equation, we are rewarded with a highly scalable, efficient and very cost-effective GMP differentiation process for PSCs to produce safe live cell therapy products on a multi-billion cell scale.
,,
ICM
| Stéphanie Bigou, Responsable Opérationnelle
We have been using the (iCS-Digital™) tests since their launch in 2018 and find them to be very reliable.
,,
Ncardia
| Arie Reijerkerk, Director Manufacturing Technology
The results are obtained very quickly; the reports are clearly interpreted and there is a smooth line of communication between Ncardia and Stem Genomics whenever we require further clarifications.
,,
Précédent
Suivant

Published scientific articles
citing the iCS-digital™ PSC assay

2023

Generation of AAVS1 and CLYBL STRAIGHT-IN v2 acceptor human iPSC lines for integrating DNA payloads

Albert Blanch-Asensio, Babet van der Vaart, Mariana Vinagre, Eline Groen, Christiaan Arendzen, Christian Freund, Niels Geijsen, Christine L. Mummery, Richard P. Davis.
2022

Modeling PRPF31 retinitis pigmentosa using retinal pigment epithelium and organoids combined with gene augmentation rescue.

Rodrigues A, Slembrouck-Brec A, Nanteau C, Terray A, Tymoshenko Y, Zagar Y, Reichman S, Xi Z, Sahel JA, Fouquet S, Orieux G, Nandrot EF, Byrne LC, Audo I, Roger JE, Goureau O. Modeling PRPF31 retinitis pigmentosa using retinal pigment epithelium and organoids combined with gene augmentation rescue. NPJ Regen Med. 2022 Aug 16;7(1):39. doi: 10.1038/s41536-022- 00235-6. PMID: 35974011; PMCID: PMC9381579.
2022

CRISPR/Cas9-mediated gene knockout and interallelic gene conversion in human induced pluripotent stem cells using non-integrative bacteriophage-chimeric retrovirus-like particles.

Mianné J, Nasri A, Van CN, Bourguignon C, Fieldès M, Ahmed E, Duthoit C, Martin N, Parrinello H, Louis A, Iché A, Gayon R, Samain F, Lamouroux L, Bouillé P, Bourdin A, Assou S, De Vos J. CRISPR/Cas9-mediated gene knockout and interallelic gene conversion in human induced pluripotent stem cells using non-integrative bacteriophage-chimeric retrovirus-like particles. BMC Biol. 2022 Jan 7;20(1):8.
2021

PCSK9 regulates the NODAL signaling pathway and cellular proliferation in hiPSCs.

Roudaut M, Idriss S, Caillaud A, Girardeau A, Rimbert A, Champon B, David A, Lévêque A, Arnaud L, Pichelin M, Prieur X, Prat A, Seidah NG, Zibara K, Le May C, Cariou B, Si-Tayeb K. PCSK9 regulates the NODAL signaling pathway and cellular proliferation in hiPSCs. Stem Cell Reports. 2021 Dec 14;16(12):2958-2972.
2021

Optogenetically controlled human functional motor endplate for testing botulinum neurotoxins.

de Lamotte JD, Polentes J, Roussange F, Lesueur L, Feurgard P, Perrier A, Nicoleau C, Martinat C. Optogenetically controlled human functional motor endplate for testing botulinum neurotoxins. Stem Cell Res Ther. 2021 Dec 5;12(1):599.
2021

Allele-Specific Knockout by CRISPR/Cas to Treat Autosomal Dominant Retinitis Pigmentosa Caused by the G56R Mutation in NR2E3.

Diakatou M, Dubois G, Erkilic N, Sanjurjo-Soriano C, Meunier I, Kalatzis V. Allele-Specific Knockout by CRISPR/Cas to Treat Autosomal Dominant Retinitis Pigmentosa Caused by the G56R Mutation in NR2E3. Int J Mol Sci. 2021 Mar 5;22(5):2607.
2020

Generation of a human induced pluripotent stem cell line (iPSC) from peripheral blood mononuclear cells of a patient with a myasthenic syndrome due to mutation in COLQ.

Barbeau S, Desprat R, Eymard B, Martinat C, Lemaitre JM, Legay C. Generation of a human induced pluripotent stem cell line (iPSC) from peripheral blood mononuclear cells of a patient with a myasthenic syndrome due to mutation in COLQ. Stem Cell Res. 2020 Dec;49:102106.
2020

Effective Differentiation and Biological Characterization of Retinal Pigment Epithelium Derived from Human Induced Pluripotent Stem Cells.

Shrestha R, Wen YT, Tsai RK. Effective Differentiation and Biological Characterization of Retinal Pigment Epithelium Derived from Human Induced Pluripotent Stem Cells. Curr Eye Res. 2020 Sep;45(9):1155-1167.
2020

Recurrent Genetic Abnormalities in Human Pluripotent Stem Cells: Definition and Routine Detection in Culture Supernatant by Targeted Droplet Digital PCR.

Assou S, Girault N, Plinet M, Bouckenheimer J, Sansac C, Combe M, Mianné J, Bourguignon C, Fieldes M, Ahmed E, Commes T, Boureux A, Lemaître JM, De Vos J. Stem Cell Reports 2020 Jan 14;14(1):1-8
2019

Generation of hiPSC line TCIERi001-A from normal human epidermal keratinocytes.

Shrestha R, Wen YT, Tsai RK. Generation of hiPSC line TCIERi001-A from normal human epidermal keratinocytes. Stem Cell Res. 2019 Dec;41:101590.
2019

Genome Editing in Patient iPSCs Corrects the Most Prevalent USH2A Mutations and Reveals Intriguing Mutant mRNA Expression Profiles.

Sanjurjo-Soriano C, Erkilic N, Baux D, Mamaeva D, Hamel CP, Meunier I, Roux AF, Kalatzis V. Genome Editing in Patient iPSCs Corrects the Most Prevalent USH2A Mutations and Reveals Intriguing Mutant mRNA Expression Profiles. Mol Ther Methods Clin Dev. 2019 Nov 27;17:156- 173.
2019

Human pre-valvular endocardial cells derived from pluripotent stem cells recapitulate cardiac pathophysiological valvulogenesis.

Neri T, Hiriart E, van Vliet PP, Faure E, Norris RA, Farhat B, Jagla B, Lefrancois J, Sugi Y, Moore- Morris T, Zaffran S, Faustino RS, Zambon AC, Desvignes JP, Salgado D, Levine RA, de la Pompa JL, Terzic A, Evans SM, Markwald R, Pucéat M. Human pre-valvular endocardial cells derived from pluripotent stem cells recapitulate cardiac pathophysiological valvulogenesis. Nat Commun. 2019 Apr 26;10(1):1929.
Précédent
Suivant

Download this file immediately

Please enter your e-mail address.